Asymmetric Synthesis of C-1 Substituted Cocaine Analogues
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors
Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2012 Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors Marisa Rosenberg Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2715 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. ANTINOCICEPTIVE EFFECTS OF MONOAMINE REUPTAKE INHIBITORS IN ASSAYS OF PAIN-STIMULATED AND PAIN-DEPRESSED BEHAVIOR A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University By Marisa B. Rosenberg Bachelor of Science, Temple University, 2008 Advisor: Sidney Stevens Negus, Ph.D. Professor, Department of Pharmacology/Toxicology Virginia Commonwealth University Richmond, VA May, 2012 Acknowledgement First and foremost, I’d like to thank my advisor Dr. Steven Negus, whose unwavering support, guidance and patience throughout my graduate career has helped me become the scientist I am today. His dedication to education, learning and the scientific process has instilled in me a quest for knowledge that I will continue to pursue in life. His thoroughness, attention to detail and understanding of pharmacology has been exemplary to a young person like me just starting out in the field of science. I’d also like to thank all of my committee members (Drs. -
Iodine(V) Reagents in Organic Synthesis. Part 4. O-Iodoxybenzoic Acid As a Chemospecific Tool for Single Electron Transfer-Based Oxidation Processes K
Published on Web 02/16/2002 Iodine(V) Reagents in Organic Synthesis. Part 4. o-Iodoxybenzoic Acid as a Chemospecific Tool for Single Electron Transfer-Based Oxidation Processes K. C. Nicolaou,* T. Montagnon, P. S. Baran, and Y.-L. Zhong Contribution from the Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, and Department of Chemistry and Biochemistry, UniVersity of California, San Diego, 9500 Gilman DriVe, La Jolla, California 92093 Received September 4, 2001 Abstract: o-Iodoxybenzoic acid (IBX), a readily available hypervalent iodine(V) reagent, was found to be highly effective in carrying out oxidations adjacent to carbonyl functionalities (to form R,â-unsaturated carbonyl compounds) and at benzylic and related carbon centers (to form conjugated aromatic carbonyl systems). Mechanistic investigations led to the conclusion that these new reactions are initiated by single electron transfer (SET) from the substrate to IBX to form a radical cation which reacts further to give the final products. Fine-tuning of the reaction conditions allowed remarkably selective transformations within multifunctional substrates, elevating the status of this reagent to that of a highly useful and chemoselective oxidant. Introduction In the preceding three papers,1-3 we have presented an array of useful transformations mediated by the iodine(V)-based reagents Dess-Martin periodinane (DMP), o-iodoxybenzoic acid (IBX), and Ac-IBX (see Figure 1). In the current paper, we expand on this theme with a description of a powerful new methodology which employs IBX for the facile and selective oxidation adjacent to carbonyl and aromatic moieties. -
Dopamine Reuptake Transporter (DAT) “Inverse Agonism” E Anovel 66 2 67 3 Hypothesis to Explain the Enigmatic Pharmacology of Cocaine 68 4 * 69 5 Q5 David J
NP5526_proof ■ 24 June 2014 ■ 1/22 Neuropharmacology xxx (2014) 1e22 55 Contents lists available at ScienceDirect 56 57 Neuropharmacology 58 59 60 journal homepage: www.elsevier.com/locate/neuropharm 61 62 63 64 65 1 Dopamine reuptake transporter (DAT) “inverse agonism” e Anovel 66 2 67 3 hypothesis to explain the enigmatic pharmacology of cocaine 68 4 * 69 5 Q5 David J. Heal , Jane Gosden, Sharon L. Smith 70 6 71 RenaSci Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK 7 72 8 73 9 article info abstract 74 10 75 11 76 Article history: The long held view is cocaine's pharmacological effects are mediated by monoamine reuptake inhibition. 12 Available online xxx However, drugs with rapid brain penetration like sibutramine, bupropion, mazindol and tesofensine, 77 13 which are equal to or more potent than cocaine as dopamine reuptake inhibitors, produce no discernable 78 14 Keywords: subjective effects such as drug “highs” or euphoria in drug-experienced human volunteers. Moreover 79 15 Cocaine they are dysphoric and aversive when given at high doses. In vivo experiments in animals demonstrate 80 16 Dopamine reuptake inhibitor that cocaine's monoaminergic pharmacology is profoundly different from that of other prescribed 81 Dopamine releasing agent 17 monoamine reuptake inhibitors, with the exception of methylphenidate. These findings led us to 82 Dopamine transporter fi 18 Inverse agonist conclude that the highly unusual, stimulant pro le of cocaine and related compounds, eg methylphe- 83 19 DAT inverse agonist nidate, is not mediated by monoamine reuptake inhibition alone. 84 We describe the experimental findings which suggest cocaine serves as a negative allosteric 20 Novel mechanism 85 21 modulator to alter the function of the dopamine reuptake transporter (DAT) and reverse its direction of fi 86 22 transport. -
Prof. J. Masson Gulland, F.R.S
702 NATURE November 22, 1947 Vol. 160 The general discussion was opened by Dr. W. K. Slater. He emphasized that the additional production OBITUARIES of food from sources in Great Britain means increased supplies of materials, for example, for additional Prof. J. Masson Gulland, F.R.S. factories and plant for extracting sugar-beet and for IT was with a sense of severe personal loss that housing poultry. The training of the human element his many friends learned of the untimely death of in more efficient methods of cultivation and of Prof. J. M. Gulland, who was a victim of the railway management of stock is likely to be a formidable accident at Goswick on October 26. He was a leading task. He asked whether a true appreciation of the figure in the chemical world, a pioneer worker in immediate future position in Great Britain is rather several important fields of organic chemistry and that the number of calories per person and the biochemistry, and a man of outstanding personal nutritional value of the average diet generally are charm. much more likely to fall than to rise ; and how far John Masson Gulland was born in Edinburgh in this fall could go without acute sequelre. 1898 and was the only son of the late Prof. G. Lovell Dr. N. C. Wright considered that a matter of Gulland, professor of medicine in the University of immediate importance is the prevention of wastage, Edinburgh. Gulland was much devoted to his native from whatever cause, of food already produced. We land, and above all to his native city, which ho must find out, for example, exactly what happens to frequently visited. -
Process for Producing Optically Active Tropinone Monocarboxylic Acid Derivative
Europäisches Patentamt *EP001118674A1* (19) European Patent Office Office européen des brevets (11) EP 1 118 674 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: C12P 17/10 25.07.2001 Bulletin 2001/30 (86) International application number: (21) Application number: 99929794.8 PCT/JP99/03754 (22) Date of filing: 12.07.1999 (87) International publication number: WO 00/18946 (06.04.2000 Gazette 2000/14) (84) Designated Contracting States: • NAKAMURA, Soichi, Nihon Medi-physics K. K. AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Sodegaura-shi, Chiba 299-0241 (JP) MC NL PT SE • NAKAMURA, Daisaku Ichihara-shi, Chiba 299-0115 (JP) (30) Priority: 30.09.1998 JP 27786898 (74) Representative: Keen, Celia Mary (71) Applicant: Nihon Medi-Physics Co., Ltd. J.A. Kemp & Co. Nishinomiya-shi, Hyogo 662-0918 (JP) 14 South Square Gray’s Inn (72) Inventors: London WC1R 5JJ (GB) • NODE, Manabu Hirakata-shi, Osaka 573-1118 (JP) (54) PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE (57) An optically active tropinonemonocarboxylic tained from natural cocaine, it was proved that the ob- acid ester derivative useful as an intermediate for syn- tained optically active tropinonemonocarboxylic acid es- thesis of optically active tropane derivatives was ob- ter derivative had the same absolute configuration as tained by reacting succindialdehyde with an organic that of natural cocaine. The yield of the optically active amine and acetonedicarboxylic acid ester to obtain a tropinonemonocarboxylic acid ester derivative from the tropinonedicarboxylic acid ester derivative, and then asymmetric dealkoxycarbonylation was 30 to 50 mol%, subjecting this derivative to enzyme-catalyzed asym- and its optical purity was 70 to 97%ee. -
Tropinone Synthesis Via an Atypical Polyketide Synthase and P450-Mediated Cyclization
ARTICLE DOI: 10.1038/s41467-018-07671-3 OPEN Tropinone synthesis via an atypical polyketide synthase and P450-mediated cyclization Matthew A. Bedewitz 1, A. Daniel Jones 2,3, John C. D’Auria 4 & Cornelius S. Barry 1 Tropinone is the first intermediate in the biosynthesis of the pharmacologically important tropane alkaloids that possesses the 8-azabicyclo[3.2.1]octane core bicyclic structure that defines this alkaloid class. Chemical synthesis of tropinone was achieved in 1901 but the 1234567890():,; mechanism of tropinone biosynthesis has remained elusive. In this study, we identify a root- expressed type III polyketide synthase from Atropa belladonna (AbPYKS) that catalyzes the formation of 4-(1-methyl-2-pyrrolidinyl)-3-oxobutanoic acid. This catalysis proceeds through a non-canonical mechanism that directly utilizes an unconjugated N-methyl-Δ1-pyrrolinium cation as the starter substrate for two rounds of malonyl-Coenzyme A mediated decarbox- ylative condensation. Subsequent formation of tropinone from 4-(1-methyl-2-pyrrolidinyl)-3- oxobutanoic acid is achieved through cytochrome P450-mediated catalysis by AbCYP82M3. Silencing of AbPYKS and AbCYP82M3 reduces tropane levels in A. belladonna. This study reveals the mechanism of tropinone biosynthesis, explains the in planta co-occurrence of pyrrolidines and tropanes, and demonstrates the feasibility of tropane engineering in a non- tropane producing plant. 1 Department of Horticulture, Michigan State University, East Lansing, MI 48824, USA. 2 Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA. 3 Department of Chemistry, Michigan State University, East Lansing, MI 48824, USA. 4 Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, TX 79409, USA. -
December Cume
Organic Cumulative Exam December 1, 2001 The Chemistry of Professor Eric Sorenson (PLEASE WRITE ALL ANSWERS ON THE FRONT PAGE OF THE EXAM) Professor Sorenson often derives ideas for his synthetic approaches by speculating on the reactions that are involved in the biosynthesis of the target molecule. That is, his synthetic approaches are "biomimetic". Sorenson also noted that this is not a new approach in organic synthesis. He cited Sir Robert Robinson's synthesis of tropinone. Long, long ago, Robinson took heed of the suggestion that enzymatic Mannich reactions might be involved in the biosynthesis of some alkaloids and used a Mannich reaction to prepare tropinone. (J. Chem. Soc. 1917, 762) 1. Give the structure of tropinone and show a detailed mechanism for the reaction: Hint: Remember that intramolecular reactions are faster than analogous intermolecular reactions. O O H+ H + CH3NH2 + H O Tropinone Hint: formula C8H13NO 2. Some questions regarding Professor Sorenson's synthesis of (-)-hispidospermidin (shown below): J. Am. Chem. Soc. 2000, 122, 9556. Reagents and conditions: (a) 2,4,6-triisopropylbenzenesulfonyl hydrazide, HCl (1.2 equiv), CH3CN, room temperature, 75%. (b) n-BuLi (2.05 equiv), Et2O/THF, -78 to -20 C; then MgBr2·OEt2, -78 C; then 7, -78 C to room temperature, 55% from 8. (c) SEMCl, n-Bu4NI, i-Pr2NEt, CH2Cl2, 50 C, ca. 100%. (d) Dibal-H, toluene, -78 C, 93%. (e) (COCl)2, DMSO, CH2Cl2, -78 C; then i-Pr2NEt, -78 C to room temperature, ca. 100%. (f) AcOH, room temperature, 2 d, 83% or AcOH, 80 C, 3 h, 87%. (g) (COCl)2, DMSO, CH2Cl2, -78 C; then i-Pr2NEt, -78 C to room temperature, ca. -
Tropane and Granatane Alkaloid Biosynthesis: a Systematic Analysis
Office of Biotechnology Publications Office of Biotechnology 11-11-2016 Tropane and Granatane Alkaloid Biosynthesis: A Systematic Analysis Neill Kim Texas Tech University Olga Estrada Texas Tech University Benjamin Chavez Texas Tech University Charles Stewart Jr. Iowa State University, [email protected] John C. D’Auria Texas Tech University Follow this and additional works at: https://lib.dr.iastate.edu/biotech_pubs Part of the Biochemical and Biomolecular Engineering Commons, and the Biotechnology Commons Recommended Citation Kim, Neill; Estrada, Olga; Chavez, Benjamin; Stewart, Charles Jr.; and D’Auria, John C., "Tropane and Granatane Alkaloid Biosynthesis: A Systematic Analysis" (2016). Office of Biotechnology Publications. 11. https://lib.dr.iastate.edu/biotech_pubs/11 This Article is brought to you for free and open access by the Office of Biotechnology at Iowa State University Digital Repository. It has been accepted for inclusion in Office of Biotechnology Publicationsy b an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Tropane and Granatane Alkaloid Biosynthesis: A Systematic Analysis Abstract The tropane and granatane alkaloids belong to the larger pyrroline and piperidine classes of plant alkaloids, respectively. Their core structures share common moieties and their scattered distribution among angiosperms suggest that their biosynthesis may share common ancestry in some orders, while they may be independently derived in others. Tropane and granatane alkaloid diversity arises from the myriad modifications occurring ot their core ring structures. Throughout much of human history, humans have cultivated tropane- and granatane-producing plants for their medicinal properties. This manuscript will discuss the diversity of their biological and ecological roles as well as what is known about the structural genes and enzymes responsible for their biosynthesis. -
Cocaine: Pharmacology, Effects, and Treatment of Abuse
Cocaine: Pharmacology, Effects, and Treatment of Abuse U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Cocaine: Pharmacology, Effects, and Treatment of Abuse Editor: John Grabowski, Ph.D. Division of Clinical Research National Institute on Drug Abuse NIDA Research Monograph 50 1984 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY, COHEN M.D. Temple University School of Medicine LosAngeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic Institute National Federation of Parents for Troy, New York Drug Free Youth RICHARD BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTMAN Langley Porter Neuropsychiatric Institute San Francisco, California Alcohol and Drug Problems Association of North America Washington, D.C. DENISE KANDEL, Ph.D. GILBERT J. BOVTIN, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V. -
Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists
The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Author(s): Peter Stout, Katherine Moore, Megan Grabenauer, Jeri Ropero-Miller Document No.: 241444 Date Received: March 2013 Award Number: 2010-DN-BX-K177 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Award Number: 2010-DN-BX-K177 July 16, 2012 Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Final Report Authors: Peter Stout Katherine Moore Megan Grabenauer Jeri Ropero-Miller This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Expansion of a Cheminformatic Database of Spectral Data for Forensic Chemists and Toxicologists Table of Contents Abstract ........................................................................................................................................... 1 Executive Summary ....................................................................................................................... -
Director's Report 2/01
Director's Report 2/01 Director's Report to the National Advisory Council on Drug Abuse February, 2001 Index Research Findings Basic Research Behavioral Research Treatment Research and Development Research on AIDS and Other Medical Consequences of Drug Abuse Epidemiology, Etiology and Prevention Research Services Research Intramural Research Program Activities Extramural Policy and Review Activities Congressional Affairs International Activities Meetings and Conferences Media and Education Activities Planned Meetings Publications Staff Highlights Grantee Honors [Office of Director] [First Report Section] Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? _ See our Contact Information. https://archives.drugabuse.gov/DirReports/DirRep201/DirectorRepIndex.html[11/17/16, 9:48:57 PM] Director's Report 2/01 - Basic Research Director's Report to the National Advisory Council on Drug Abuse February, 2001 Research Findings Basic Research Role for GDNF in Biochemical and Behavioral Adaptations to Drugs of Abuse Drs. David Russell and Eric Nestler and their research team at the Yale University examined a role for Glial-Derived Neurotrophic Factor (GDNF) in adaptations to drugs of abuse. Infusion of GDNF into the ventral tegmental area (VTA), a dopaminergic brain region important for addiction, blocks certain biochemical adaptations to chronic cocaine or morphine as well as the rewarding effects of cocaine. Conversely, responses to cocaine are enhanced in rats by intra-VTA infusion of an anti-GDNF antibody and in mice heterozygous for a null mutation in the GDNF gene. -
List of Narcotic Drugs Under International Control
International Narcotics Control Board Yellow List Annex to Forms A, B and C 59th edition, July 2020 LIST OF NARCOTIC DRUGS UNDER INTERNATIONAL CONTROL Prepared by the INTERNATIONAL NARCOTICS CONTROL BOARD* Vienna International Centre P.O. Box 500 A-1400 Vienna, Austria Internet address: http://www.incb.org/ in accordance with the Single Convention on Narcotic Drugs, 1961** Protocol of 25 March 1972 amending the Single Convention on Narcotic Drugs, 1961 * On 2 March 1968, this organ took over the functions of the Permanent Central Narcotics Board and the Drug Supervisory Body, r etaining the same secretariat and offices. ** Subsequently referred to as “1961 Convention”. V.20-03697 (E) *2003697* Purpose The Yellow List contains the current list of narcotic drugs under international control and additional relevant information. It has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical reports on narcotic drugs (Form C), the quarterly statistics of imports and exports of narcotic drugs (Form A) and the estimates of annual requirements for narcotic drugs (Form B) as well as related questionnaires. The Yellow List is divided into four parts: Part 1 provides a list of narcotic drugs under international control in the form of tables and is subdivided into three sections: (1) the first section includes the narcotic drugs listed in Schedule I of the 1961 Convention as well as intermediate opiate raw materials; (2) the second section includes the narcotic drugs listed in Schedule II of the 1961 Convention; and (3) the third section includes the narcotic drugs listed in Schedule IV of the 1961 Convention.